読み込み中
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
前日終値
$0.794
+$0.0247 · +3.21%
日中の時刻はETです。市場データは遅延する場合があります。
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
日中レンジ
現在 $0.794
52週レンジ
現在 $0.794
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
42
まちまち
リスク
75
高リスク
モメンタム
24
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
日中レンジ
現在 $0.794
52週レンジ
現在 $0.794
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 1000 USD | — | — | — | — |
| 粗利益 | −1000 USD | — | — | — | — |
| 研究開発 | 1102.9万 USD | 1424.8万 USD | 3991 USD | 1.8万 USD | 1.7万 USD |
| 販売・一般管理 | 1090.2万 USD | 1386.4万 USD | 1.14万 USD | 9680 USD | 9597 USD |
| 営業費用 | 2193万 USD | 6511.2万 USD | 1.63万 USD | 2.76万 USD | 2.66万 USD |
| 受取利息 | — | 40万 USD | 600 USD | — | — |
| 減価償却費と償却費 | 1000 USD | 6.3万 USD | 11.9万 USD | 16.9万 USD | 12.1万 USD |
| 営業利益 | −2193.1万 USD | −6511.2万 USD | −1.63万 USD | −2.76万 USD | −2.66万 USD |
| 純利益 | −4987.1万 USD | −6288.3万 USD | −1.57万 USD | −2.73万 USD | −2.62万 USD |
会社概要が更新されました 2026年10月11日.
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
